Your browser doesn't support javascript.
SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate.
Olagnier, David; Farahani, Ensieh; Thyrsted, Jacob; Blay-Cadanet, Julia; Herengt, Angela; Idorn, Manja; Hait, Alon; Hernaez, Bruno; Knudsen, Alice; Iversen, Marie Beck; Schilling, Mirjam; Jørgensen, Sofie E; Thomsen, Michelle; Reinert, Line S; Lappe, Michael; Hoang, Huy-Dung; Gilchrist, Victoria H; Hansen, Anne Louise; Ottosen, Rasmus; Nielsen, Camilla G; Møller, Charlotte; van der Horst, Demi; Peri, Suraj; Balachandran, Siddharth; Huang, Jinrong; Jakobsen, Martin; Svenningsen, Esben B; Poulsen, Thomas B; Bartsch, Lydia; Thielke, Anne L; Luo, Yonglun; Alain, Tommy; Rehwinkel, Jan; Alcamí, Antonio; Hiscott, John; Mogensen, Trine H; Paludan, Søren R; Holm, Christian K.
  • Olagnier D; Department of Biomedicine, Aarhus Research Center for Innate Immunology, Aarhus University, Aarhus, Denmark. olagnier@biomed.au.dk.
  • Farahani E; Department of Biomedicine, Aarhus Research Center for Innate Immunology, Aarhus University, Aarhus, Denmark.
  • Thyrsted J; Department of Biomedicine, Aarhus Research Center for Innate Immunology, Aarhus University, Aarhus, Denmark.
  • Blay-Cadanet J; Department of Biomedicine, Aarhus Research Center for Innate Immunology, Aarhus University, Aarhus, Denmark.
  • Herengt A; Department of Biomedicine, Aarhus Research Center for Innate Immunology, Aarhus University, Aarhus, Denmark.
  • Idorn M; Department of Biomedicine, Aarhus Research Center for Innate Immunology, Aarhus University, Aarhus, Denmark.
  • Hait A; Department of Biomedicine, Aarhus Research Center for Innate Immunology, Aarhus University, Aarhus, Denmark.
  • Hernaez B; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
  • Knudsen A; Centro de Biología Molecular Severo Ochoa (Consejo Superior de Investigaciones Científicas - Universidad Autónoma de Madrid), Nicolás Cabrera 1, 28049, Madrid, Spain.
  • Iversen MB; Department of Biomedicine, Aarhus Research Center for Innate Immunology, Aarhus University, Aarhus, Denmark.
  • Schilling M; Department of Biomedicine, Aarhus Research Center for Innate Immunology, Aarhus University, Aarhus, Denmark.
  • Jørgensen SE; Medical Research Council Human Immunology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9DS, UK.
  • Thomsen M; Department of Biomedicine, Aarhus Research Center for Innate Immunology, Aarhus University, Aarhus, Denmark.
  • Reinert LS; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
  • Lappe M; Department of Biomedicine, Aarhus Research Center for Innate Immunology, Aarhus University, Aarhus, Denmark.
  • Hoang HD; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
  • Gilchrist VH; Department of Biomedicine, Aarhus Research Center for Innate Immunology, Aarhus University, Aarhus, Denmark.
  • Hansen AL; Omiics ApS, Åbogade 15, 8200, Aarhus N, Denmark.
  • Ottosen R; Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry Microbiology and Immunology, University of Ottawa, Ottawa, ON, K1H 8L1, Canada.
  • Nielsen CG; Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry Microbiology and Immunology, University of Ottawa, Ottawa, ON, K1H 8L1, Canada.
  • Møller C; Department of Biomedicine, Aarhus Research Center for Innate Immunology, Aarhus University, Aarhus, Denmark.
  • van der Horst D; Department of Chemistry, Aarhus University, Aarhus, Denmark.
  • Peri S; Department of Biomedicine, Aarhus Research Center for Innate Immunology, Aarhus University, Aarhus, Denmark.
  • Balachandran S; Department of Biomedicine, Aarhus Research Center for Innate Immunology, Aarhus University, Aarhus, Denmark.
  • Huang J; Department of Biomedicine, Aarhus Research Center for Innate Immunology, Aarhus University, Aarhus, Denmark.
  • Jakobsen M; Fox Chase Cancer Center, 333 Cottman Avenue, Philidelphia, PA, 19111-2497, USA.
  • Svenningsen EB; Fox Chase Cancer Center, 333 Cottman Avenue, Philidelphia, PA, 19111-2497, USA.
  • Poulsen TB; Lars Bolund Institute of Regenerative Medicine, BGI-Shenzhen, Shenzhen, 518083, China.
  • Bartsch L; Department of Biology, University of Copenhagen, 2100, Copenhagen, Denmark.
  • Thielke AL; Department of Biomedicine, Aarhus Research Center for Innate Immunology, Aarhus University, Aarhus, Denmark.
  • Luo Y; Department of Chemistry, Aarhus University, Aarhus, Denmark.
  • Alain T; Department of Chemistry, Aarhus University, Aarhus, Denmark.
  • Rehwinkel J; Department of Pediatrics and Adolescent Medicine, Division of Pediatric Neurology, University Medical Center Göttingen, 37075, Göttingen, Germany.
  • Alcamí A; Department of Biomedicine, Aarhus Research Center for Innate Immunology, Aarhus University, Aarhus, Denmark.
  • Hiscott J; Department of Biomedicine, Aarhus Research Center for Innate Immunology, Aarhus University, Aarhus, Denmark.
  • Mogensen TH; Lars Bolund Institute of Regenerative Medicine, BGI-Shenzhen, Shenzhen, 518083, China.
  • Paludan SR; Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry Microbiology and Immunology, University of Ottawa, Ottawa, ON, K1H 8L1, Canada.
  • Holm CK; Medical Research Council Human Immunology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9DS, UK.
Nat Commun ; 11(1): 4938, 2020 10 02.
Artículo en Inglés | MEDLINE | ID: covidwho-811574
ABSTRACT
Antiviral strategies to inhibit Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) and the pathogenic consequences of COVID-19 are urgently required. Here, we demonstrate that the NRF2 antioxidant gene expression pathway is suppressed in biopsies obtained from COVID-19 patients. Further, we uncover that NRF2 agonists 4-octyl-itaconate (4-OI) and the clinically approved dimethyl fumarate (DMF) induce a cellular antiviral program that potently inhibits replication of SARS-CoV2 across cell lines. The inhibitory effect of 4-OI and DMF extends to the replication of several other pathogenic viruses including Herpes Simplex Virus-1 and-2, Vaccinia virus, and Zika virus through a type I interferon (IFN)-independent mechanism. In addition, 4-OI and DMF limit host inflammatory responses to SARS-CoV2 infection associated with airway COVID-19 pathology. In conclusion, NRF2 agonists 4-OI and DMF induce a distinct IFN-independent antiviral program that is broadly effective in limiting virus replication and in suppressing the pro-inflammatory responses of human pathogenic viruses, including SARS-CoV2.
Asunto(s)

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Antivirales / Neumonía Viral / Succinatos / Infecciones por Coronavirus / Factor 2 Relacionado con NF-E2 / Dimetilfumarato / Betacoronavirus / Antiinflamatorios Tipo de estudio: Estudio pronóstico Tópicos: Vacunas Límite: Adulto / Femenino / Humanos / Masculino Idioma: Inglés Revista: Nat Commun Asunto de la revista: Biologia / Ciencia Año: 2020 Tipo del documento: Artículo País de afiliación: S41467-020-18764-3

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Antivirales / Neumonía Viral / Succinatos / Infecciones por Coronavirus / Factor 2 Relacionado con NF-E2 / Dimetilfumarato / Betacoronavirus / Antiinflamatorios Tipo de estudio: Estudio pronóstico Tópicos: Vacunas Límite: Adulto / Femenino / Humanos / Masculino Idioma: Inglés Revista: Nat Commun Asunto de la revista: Biologia / Ciencia Año: 2020 Tipo del documento: Artículo País de afiliación: S41467-020-18764-3